Judge OKs Fresenius Backing Out of Akorn Acquisition
As a result of the ruling, we’re raising our fair value on Fresenius and lowering our fair value on Akorn.
A Delaware judge sided with Fresenius SE (FRE) in the company’s attempt to block its acquisition of Akorn (AKRX) over material manufacturing and data integrity issues. While the ordeal raises concerns about Fresenius’ due diligence efforts leading up to the acquisition announcement, the judge’s ruling is nonetheless a positive for Fresenius financially as well as strategically. We’re raising our fair value estimate for Fresenius to $65 per share, essentially on par with our fair value estimate before the dramatic decline in Akorn’s performance. Given Akorn’s poor operating performance after the deal was announced, we had lowered our fair value estimate as a result of potential capital destruction at the previously agreed price. Fresenius’ ability to back out of the deal also helps protect the company’s narrow economic moat, in our view, even though Akorn would have been a small contributor to the company’s large, diversified operations. We’re lowering our fair value estimate for no-moat Akorn to $10 per share. Our previous $16 fair value estimate included a 25% probability that Fresenius would be legally forced to purchase Akorn at the previously agreed $34 share price.
Although Akorn intends to appeal the decision, we think this ruling creates even more doubt regarding the company’s ability to uphold the original merger agreement. We’re therefore comfortable removing the effect of the deal on our assumptions for both companies. Furthermore, we think this event--especially with known concerns about the company's operating practices--will make it difficult for Akorn to find other potential buyers. While we long expected Akorn to be a takeout target, we think recent challenges in the generic drug industry will slow generic drug manufacturer consolidation as well as diminish the appeal of certain complex generic categories. We imagine Akorn will struggle as a stand-alone entity even though it is arguably still better positioned than some peers.
|Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.|
Michael Waterhouse does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.